TD Cowen analyst Charles Rhyee has maintained their bullish stance on CAH stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Charles Rhyee has given his Buy rating due to a combination of factors that highlight Cardinal Health’s strong performance and strategic initiatives. The company has demonstrated core growth that exceeds its long-term target of 5-7%, indicating robust underlying business drivers. Despite concerns about the Pharma segment’s recent performance, management’s guidance adjustments and consistent communication of strong trends are seen as positive indicators for future growth.
Additionally, the strength in Cardinal Health’s ‘Other’ segment, which contributes significantly to adjusted operating income, is encouraging, with double-digit growth reported. The Solaris acquisition is also viewed positively, as it supports the company’s multispecialty strategy and is expected to contribute significantly to sales and adjusted EBITDA. These factors, along with an adjusted EPS estimate increase and a maintained price target, underpin Rhyee’s Buy rating for Cardinal Health.
In another report released today, Leerink Partners also maintained a Buy rating on the stock with a $186.00 price target.